Core Viewpoint - Chengda Pharmaceutical (301201.SZ) is currently experiencing a decline in stock price, closing at 40.70 yuan with a drop of 3.85%, indicating it is in a state of breaking below its initial public offering price [1] Group 1: IPO and Financials - Chengda Pharmaceutical was listed on the Shenzhen Stock Exchange's Growth Enterprise Market on January 20, 2022, with an initial public offering of 24,174,035 shares at a price of 72.69 yuan per share [1] - The highest price recorded on the first day of trading was 188.00 yuan, marking the peak since its listing [1] - The total funds raised from the IPO amounted to 1,757.21 million yuan, with a net amount of 1,621.45 million yuan after deducting issuance costs [1] - The actual net fundraising exceeded the original target by 1,108.17 million yuan, with the initial target set at 513.28 million yuan for projects including pharmaceutical intermediates, raw materials, and R&D center expansion [1] Group 2: Shareholder Returns - On July 3, 2023, Chengda Pharmaceutical announced its 2022 annual equity distribution plan, which includes a cash dividend of 3.00 yuan for every 10 shares and a capital reserve increase of 6.00 shares for every 10 shares held [2] - The record date for this equity distribution was set for July 6, 2023, with the ex-dividend date on July 7, 2023 [2] Group 3: Management - The actual controllers of Chengda Pharmaceutical are Ge Jianli, Lu Gang, and Lu Jin, with Lu Jin holding Canadian permanent residency [2]

证券之星消息，12月31日化学制药板块较上一交易日下跌0.31%，信立泰领跌。当日上证指数报收于 3968.84，上涨0.09%。深证成指报收于13525.02，下跌0.58%。化学制药板块个股涨跌见下表： | 代码 | 名称 | 主力净流入(元) | 主力净占比 游资净流入 (元) | | 游资净占比 散户净流入 (元) | | 散户净占比 | | --- | --- | --- | --- | --- | --- | --- | --- | | 300573 | 兴齐眼药 | 7439.59万 | 13.65% | -697.93万 | -1.28% | -6741.66万 | -12.37% | | 000963 | 华东医药 | 6823.36万 | 18.91% | -4988.17万 | -13.83% | -1835.19万 | -5.09% | | 300086 | 康芝药业 | 3651.55万 | 3.67% | 4453.79万 | 4.47% | -8105.34万 | -8.14% | | 301246 | 宏源药业 | 3493.05万 | 3.27% | -208.79万 | - ...

Group 1 - The core viewpoint of the news is that 海思科 (Haisco) has shown a slight increase in stock price, reaching 51.14 yuan per share, with a total market capitalization of 57.273 billion yuan as of December 31 [1] - 海思科's main business involves the research, development, production, and sales of chemical pharmaceuticals, with revenue composition as follows: anesthetic products 39.81%, cooperative product-related income 23.59%, other indications 17.02%, parenteral nutrition 10.32%, antiemetics for tumors 8.15%, and other (supplementary) 0.86% [1] Group 2 - 中欧医疗健康混合A (China Europe Medical Health Mixed A) fund has increased its holdings in 海思科 by 121,200 shares, bringing its total to 21,397,500 shares, which accounts for 4.44% of the circulating shares [2] - The fund has achieved a year-to-date return of 13.6% and a one-year return of 11.58%, ranking 5,297 out of 8,085 in its category [2] Group 3 - The fund manager of 中欧医疗健康混合A is 葛兰 (Gelan) and 赵磊 (Zhao Lei), with total fund assets of 435.44 billion yuan and 329.54 billion yuan respectively [3] - 葛兰 has a tenure of 10 years and 340 days, with the best fund return of 97.86% and the worst return of -35.13% during her tenure [3] Group 4 - 中欧医疗健康混合A has 海思科 as its tenth largest holding, representing 3.47% of the fund's net value, with a floating profit of approximately 11.1267 million yuan [4]

Core Viewpoint - The company, Borui Pharmaceutical, reported a stock price of 49.4 yuan as of December 30, 2025, with a slight decline of 0.66% and a trading volume of 41,400 shares, amounting to a total transaction value of 205 million yuan [1]. Trading Information Summary - On December 30, the main funds experienced a net outflow of 20.59 million yuan, accounting for 10.03% of the total transaction value; retail investors saw a net inflow of 12.39 million yuan, representing 6.04% of the total [2]. - The company’s stock trading saw a turnover rate of 0.98% [1]. Company Announcements Summary - The underwriting and sponsoring company, Guolian Minsheng Securities, conducted an on-site inspection of Borui Pharmaceutical for its 2025 annual continuous supervision work, confirming that the company has a sound governance structure and complies with regulations regarding fundraising and investment [2]. - The board of directors approved a proposal to postpone the expected operational status date for several fundraising projects to March 2027, due to pending product approvals and the need for additional construction of an automated warehouse [2][3]. Internal Governance and Audit - Borui Pharmaceutical established an internal audit management system to ensure independent auditing of internal controls, financial information, and operational activities, with regular reporting to the audit committee [4]. - The company also implemented a foreign exchange trading management system to mitigate exchange rate risks and ensure the safety of funds, prohibiting speculative activities [5]. Fundraising Management - The company has set up a fundraising management method to regulate the storage, use, and supervision of raised funds, ensuring they are used exclusively for designated projects and not for financial investments [6]. - Any changes in fundraising projects or surplus fund usage must go through board or shareholder meeting approval, with biannual progress checks and annual verification reports from accounting firms [6]. Shareholding Management - Borui Pharmaceutical has established a management system for shares held by directors and senior management, outlining restrictions on share transfers and trading periods, as well as disclosure requirements [7].

Group 1 - The core viewpoint of the article is that Zhejiang Zhenyuan has successfully managed its production and sales of histidine since its launch, aligning with market demand [2] Group 2 - The company has reported good production and sales conditions for histidine, indicating a positive response to market needs [2]

在相继披露了法院裁定不予受理重整申请暨子公司宣告破产、公司股票可能被实施重大违法强制退市相关风险、公司股票被叠加实施退市风险警示的公告 后，*ST长药（300391）的股价在12月30日盘中一度跌停，当天收盘价报0.95元/股，下跌19.49%。 30日晚间，*ST长药发布公告，公司股票收盘价首次低于1元，可能因连续二十个交易日股票收盘价低于1元而被终止上市。同时，公司因涉嫌定期报告等 财务数据虚假记载被证监会立案调查，可能触及重大违法强制退市情形。此外，公司2024年度期末净资产为负，若2025年度期末净资产继续为负，将被实 施财务类强制退市。公司还面临诉讼、仲裁案件风险，大额有息负债逾期风险，账户冻结风险以及大额欠税风险。 对于股价跌破1元、法院裁定不予受理重整申请的影响，以及后续措施等，上证报记者以投资者身份致电*ST长药投资者专线，公司相关人士回应："不出 意外是要退市，暂无应对措施。" 在涉嫌触及重大违法强制退市情形前，*ST长药已存在财务类强制退市风险。 同时，据公司2022年、2023年、2024年年度报告，公司2022年、2023年、2024年度经审计的扣除非经常性损益后的净利润分别为-763 ...

Core Viewpoint - Jincheng Pharmaceutical's wholly-owned subsidiary, Beijing Jincheng Tail Pharmaceutical Co., Ltd., has received the GMP compliance inspection notice from the Beijing Drug Administration for its active pharmaceutical ingredient, Mirabegron, indicating successful compliance with the 2010 revised Good Manufacturing Practice standards [1] Group 1 - The inspection took place from December 11 to 15, 2023 [1] - The scope of the inspection covered the Mirabegron production line in the second workshop [1] - The inspection conclusion confirmed that the company met the relevant standards and appendix requirements [1]

Core Viewpoint - The announcement highlights a significant contract signed by the company's wholly-owned subsidiary, Ausino, which is expected to contribute positively to the company's revenue and market position in the pharmaceutical supply chain [1][2]. Group 1: Contract Details - The contract signed on May 22, 2023, involves a total amount of approximately $102 million (including tax), with an actual performance amount of about $20 million (approximately RMB 143.53 million) for the year 2025, representing 8.83% of the company's audited revenue for 2024 and 29.05% of customized products and services revenue [1]. - The actual performance amount for 2025 exceeds the procurement guidance of $12.15 million by 65.43%, showcasing the company's technical strength and market competitiveness [1]. Group 2: Financial Impact - The successful execution of this contract is expected to have a positive impact on the company's operating performance for 2025, enhancing its sustainability and brand influence while expanding its overseas market [2]. - In the first three quarters of 2025, the company achieved revenue of RMB 1.527 billion, a year-on-year increase of 21.95%, and a net profit attributable to the parent company of RMB 445 million, up 26.92% year-on-year [2]. Group 3: International Strategy - The company has positioned internationalization as a core strategy, leveraging its technological advantages and production capacity to accelerate global market penetration [2]. - The company has established a sales network covering Europe, Latin America, India, and Africa, with peptide raw materials exported to 22 countries, including the United States, Europe, and Canada [2]. - The excess performance of the significant contract further validates the company's capability in expanding its overseas business [2].

Group 1 - The company, Shengda Bio, has a range of vitamin products including biotin and folic acid [2] - For raw material supply, the company primarily procures folic acid production materials through purchasing methods [2] - The company adopts a centralized procurement model for bulk raw materials to ensure high quality and stability of supply [2]

Core Viewpoint - The company acknowledges that drug research and development is significantly influenced by industry policies and market changes, highlighting the inherent risks associated with long cycles, high investments, and uncertainty in outcomes [2] Group 1: Drug Research and Development - The company is adjusting its drug research and development projects based on its own circumstances and external environmental factors [2] - Drug research projects that enter the registration process will have their progress disclosed through regular reports and temporary announcements [2]